Research & Development

R&D Overview Our R&D Approach Pipeline Technology Platforms Manufacturing

Other Information

Clinical Trials Expanded Access

Pipeline

Robust Product Pipeline

Our rich pipeline of product candidates demonstrates our leadership in drug development for central nervous system (CNS) diseases, a therapeutic area where we have a proven track record of success. Backed by decades of experience, we are able to streamline clinical development time and substantially increase the probability of late-stage product success. The proof is in our substantial pipeline and its potential to have a unique and positive impact for patients.

Development Candidates

Preclinical Phase 1 Phase 2 Phase 3 NDA Filed
ALKS 5461
(Major Depressive Disorder)
ALKS 3831
(Schizophrenia)
Diroximel Fumarate (BIIB098)
(Multiple Sclerosis)
ALKS 4230
(Immuno-oncology)

Learn more about our portfolio of innovative products.